Avalo Therapeutics Inc. (NASDAQ: AVTX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AVALO THERAPEUTICS INC.

Avalo Therapeutics Inc. (NASDAQ: AVTX)
Listen to this Section


$13.08
-0.5300 ( -3.89% ) 946.4K

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Clinical Trial Pipeline Stages


Drug Name Stage
AVTX-803 (CERC-803)DetailsLeukocyte Adhesion Deficiency Type II Phase 3
AVTX-009DetailsHidradenitis suppurativa, Autoimmune disease Phase 2
Quisovalimab/ AVTX-002 (CERC-002)DetailsCOVID-19 Phase 2
Quisovalimab/AVTX-002 (CERC-002)DetailsAsthma Phase 2
AVTX-007 (CERC-007)DetailsMultiple myeloma, Adult Onset Still's Disease Phase 1b
Quisovalimab/ AVTX-002 (CERC-002)DetailsCrohns disease Phase 1b
AVTX-801 (CERC-801)DetailsMetabolic disorder, Rare genetic disease Failed
AVTX-802 (CERC-802)DetailsMetabolic disorder, Rare genetic disease Failed
AVTX-006 (CERC-006)DetailsLymphatic malformations Failed

Market Data


Open $13.08
Previous Close $13.61
Volume 946.4K
Market Cap $722.25M
Day Range $13.08 - $14.70
52 Week Range $4.06 - $24.27
Shares Outstanding 52.57M
Change % -3.89%
Net Change ▼ -0.5300
Insider Ownership -0.10%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2015
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -1,231,536.00

Date Type Amount Purchased Purchaser
2024-11-14 Buy 500.00 Almenoff June Sherie
2024-08-14 Sale -24600.00 Goldman Jonathan
2024-08-14 Sale -24600.00 Chan Mitchell
2024-08-14 Sale -24600.00 Almenoff June Sherie
2024-08-14 Sale -24600.00 KANTOFF AARON
2024-08-14 Sale -24600.00 Truex Samantha
2024-08-14 Sale -24600.00 KAPLAN GILLA
2024-08-14 Sale -186700.00 Sullivan Christopher Ryan
2024-08-14 Sale -500400.00 NEIL GARRY ARTHUR
2024-07-16 Sale -234000.00 Doyle Mittie

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Mar 31, 2026
4 Insider transactions 1 Mar 31, 2026
4 Insider transactions 1 Mar 31, 2026
8-k 8K-related 12 Mar 27, 2026
s-8 Registration statements 13 Mar 23, 2026
8-k 8K-related 14 Mar 23, 2026
10-k Annual reports 87 Mar 23, 2026
4 Insider transactions 1 Mar 18, 2026
schedule Other 2 Mar 06, 2026
4 Insider transactions 1 Mar 02, 2026

Latest News


× Before browsing our site, please accept our cookies policy